Key Takeaways
- • Apollo and KKR closed a €3 billion equity capital solution for Bayer's long-acting reversible contraceptives (LARC) business on September 16, 2026, with the transaction originally announced on July 10.
- • Bayer retains majority ownership and full operational control of the LARC business; the investment represents a capital-structure solution rather than a carve-out or loss of control.
- • KKR participated as a significant minority investor alongside Apollo-managed funds in the newly established entity holding the LARC asset.
- • Apollo structured the deal through its High Grade Capital Solutions platform, positioning it as large, flexible, bespoke capital deployment to a blue-chip pharmaceutical corporate.
- • The LARC business remains fully consolidated within Bayer's Pharmaceuticals Division with no changes to strategic direction or operational structure as a result of the investment.
Summary
Apollo and KKR have successfully closed a €3 billion equity capital solution for Bayer's long-acting reversible contraceptives (LARC) business, marking completion of a transaction first announced in July 2026. The deal closed on September 16 and represents a sponsor-led minority capital investment into a ring-fenced pharmaceutical cash-flow asset, structured to provide balance-sheet and capital-structure relief while preserving Bayer's operational and strategic control.
The transaction involved the creation of a newly established entity to hold the LARC business, into which Apollo-managed funds and KKR invested equity capital. Bayer maintains majority ownership and continues to exercise full operational control of the business, with no changes to LARC strategy or operational integration within the Pharmaceuticals Division. This structure allows Bayer to retain the asset on a fully consolidated basis while monetizing a portion of its cash flow generation.
Apollo executed the investment through its High Grade Capital Solutions platform, which focuses on large, flexible, and bespoke capital solutions tailored to investment-grade corporates. KKR's participation as a significant minority investor alongside Apollo reflects strong sponsor confidence in the LARC business's cash-generation profile and market position. The deal underscores growing institutional appetite for structured capital solutions that provide corporations with balance-sheet flexibility without requiring operational or strategic concessions.
Bayer was advised by BofA Securities and Deutsche Bank, with legal counsel from Linklaters. Apollo's advisory team included Latham & Watkins, Paul Weiss, and NautaDutilh. The transaction exemplifies an alternative capital structure increasingly utilized by large pharmaceutical companies to optimize balance sheets while maintaining full business control and strategic direction.
The transaction involved the creation of a newly established entity to hold the LARC business, into which Apollo-managed funds and KKR invested equity capital. Bayer maintains majority ownership and continues to exercise full operational control of the business, with no changes to LARC strategy or operational integration within the Pharmaceuticals Division. This structure allows Bayer to retain the asset on a fully consolidated basis while monetizing a portion of its cash flow generation.
Apollo executed the investment through its High Grade Capital Solutions platform, which focuses on large, flexible, and bespoke capital solutions tailored to investment-grade corporates. KKR's participation as a significant minority investor alongside Apollo reflects strong sponsor confidence in the LARC business's cash-generation profile and market position. The deal underscores growing institutional appetite for structured capital solutions that provide corporations with balance-sheet flexibility without requiring operational or strategic concessions.
Bayer was advised by BofA Securities and Deutsche Bank, with legal counsel from Linklaters. Apollo's advisory team included Latham & Watkins, Paul Weiss, and NautaDutilh. The transaction exemplifies an alternative capital structure increasingly utilized by large pharmaceutical companies to optimize balance sheets while maintaining full business control and strategic direction.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.